Entrectinib: First Global Approval

Drugs
Zaina T Al-Salama, Susan J Keam

Abstract

Entrectinib (Rozlytrek®) is an oral selective inhibitor of the tyrosine kinases tropomyosin receptor kinases (Trk)A/B/C [encoded by the genes neurotrophic tyrosine receptor kinase (NTRK) 1, 2 and 3, respectively], c-ros oncogene 1 (ROS1) and anaplastic lymphoma kinase (ALK) with central nervous system (CNS) activity developed by Roche for the treatment of various solid tumours harbouring NTRK1/2/3 or ROS1 gene fusions. In June 2019, entrectinib received its first global approval in Japan, for the treatment of adult and paediatric patients with NTRK fusion-positive, advanced or recurrent solid tumours and is under regulatory review for the treatment of adult patients with ROS1-positive non-small cell lung cancer (NSCLC). Entrectinib is also under regulatory review in the USA (PDUFA date 18 August 2019) and EU [Priority Medicines (PRIME) designation] for NTRK-positive solid tumours and ROS1-positive NSCLC. This article summarizes the milestones in the development of entrectinib leading to this first global approval for solid tumours in Japan.

References

Oct 20, 2018·Nature Reviews. Clinical Oncology·Emiliano CoccoAlexander Drilon
Mar 7, 2020·Annals of Oncology : Official Journal of the European Society for Medical Oncology·L Paz-AresG D Demetri
Nov 1, 2018·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G D DemetriR C Doebele

❮ Previous
Next ❯

Citations

Aug 2, 2020·Expert Opinion on Pharmacotherapy·Jiyun LeeMyung-Ju Ahn
Oct 15, 2019·Frontiers in Oncology·Maritza P GarridoCarmen Romero
Jun 9, 2020·Frontiers in Pharmacology·Wenqiang CuiShuguang Yuan
Jun 20, 2020·Signal Transduction and Targeted Therapy·Rodolfo Daniel Cervantes-VillagranaSara Judit García-Acevez
Sep 4, 2020·Amino Acids·Zizhen YinVadim A Soloshonok
Nov 12, 2020·Pharmaceuticals·Nicola J NasserAbed Agbarya
Dec 5, 2020·Clinical Lung Cancer·Naoki Haratake, Takashi Seto
Oct 19, 2020·International Journal of Pharmaceutics·Yuan LiHuile Gao
Dec 19, 2020·OncoTargets and Therapy·Wan LiuWen Di
Mar 2, 2021·Acta Pharmaceutica Sinica. B·Tingting JiangLiang Ouyang
Mar 31, 2021·Journal of Medicinal Chemistry·Andrew C FlickChristopher J O'Donnell
Oct 18, 2020·Bioorganic & Medicinal Chemistry·Minghao SunJinpei Zhou
Apr 11, 2021·Biochemical Pharmacology·Michelle Melgarejo da RosaMoacyr Jesus Barreto de Melo Rego
Apr 28, 2021·European Journal of Medicinal Chemistry·Xiaoxia LiangBo Jing
May 1, 2021·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Karen Rodríguez-VillarJaime Pérez-Villanueva
Jun 1, 2021·Expert Opinion on Drug Discovery·Florian Wittlinger, Stefan A Laufer
Oct 16, 2020·Journal of Medicinal Chemistry·Liqun ChenJing Liu
Oct 9, 2021·Journal of Medicinal Chemistry·Cecilia C Ayala-AguileraAsier Unciti-Broceta
Oct 11, 2021·Bioorganic & Medicinal Chemistry Letters·Pei LiHuibin Zhang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antiparasitics

Antiparasitics are medications which are indicated for the treatment of parasitic diseases. Discover the latest research on antiparasitics here.